item management s discussion and analysis of financial condition and results of operations overview celsion is an innovative oncology drug development company focused on improving treatment for those suffering with highly aggressive and difficult to treat forms of cancer 
we are working to develop and commercialize more efficient  effective  targeted chemotherapeutic oncology drugs based on our proprietary heat activated liposomal technology 
our lead product thermodox is being tested in human clinical trials for the treatment of primary liver cancer and recurrent chest wall breast cancer 
significant events in june  the company divested and sold its medical device business assets to boston scientific 
the results from operations from the medical device business have been reclassified into discontinued operations for the years ended december  and the medical device assets were sold to boston scientific for an aggregate purchase price of million payable in three installments consisting of million at closing and million on each of the first and second anniversaries of the closing 
the company received million in cash from boston scientific in and the final  installment is due to the company in june in addition to the other indemnification provisions  such as indemnification for breaches of representations  warranties and covenants contained in the asset purchase agreement  the company agreed to indemnify boston scientific for a period of two years from the closing  in an amount up to million of incurred costs  in the event of unforeseen intellectual property claims related to the medical device assets 
the million paid at closing was reduced by approximately million  representing the principal and accrued interest due on promissory notes previously issued by the company to boston scientific  and certain royalty payments to american medical systems under the settlement and license agreement dated as of february  critical accounting policies and estimates our financial statements  which appear at item to this annual report on form k  have been prepared in accordance with accounting principles generally accepted in the united states  which require that the company make certain assumptions and estimates and  in connection therewith  adopt certain accounting policies 
our significant accounting policies are set forth in note to our financial statements 
of those policies  we believe that the policies discussed below may involve a higher degree of judgment and may be more critical to an accurate reflection of our financial condition and results of operations 
stock based compensation stock options are generally granted with an exercise price at market value at the date of the grant 
the stock options generally expire years from the date of grant 
stock option awards vest upon terms determined by the board of directors 
restricted stock awards have been granted with a vesting schedule 
the fair value of options  warrants and restricted stock granted is measured in accordance with sfas r using the black scholes option pricing model and recorded as an expense in the period in which such services are received 
the fair values of stock options granted were estimated at the date of grant using the black scholes option pricing model 
the black scholes model was originally developed 
table of contents for use in estimating the fair value of traded options  which have different characteristics from celsion s nonqualified stock options 
the model is also sensitive to changes in assumptions  which can materially affect the fair value estimate 
the company used the following assumptions for determining the fair value of options granted under the black scholes option pricing model year ended december  year ended december  risk free interest rate to to expected volatility expected life in years expected dividend yield expected volatilities utilized in the model are based on historical volatility of the company s stock price 
the risk free interest rate is derived from values assigned to us treasury strips as published in the wall street journal in effect at the time of grant 
the model incorporates exercise  pre vesting and post vesting forfeiture assumptions based on analysis of historical data 
the expected life of the fiscal grants was generated using the simplified method as allowed under securities and exchange commission staff accounting bulletin no 
we review our financial reporting and disclosure practices and accounting policies on an ongoing basis to ensure that our financial reporting and disclosure system provides accurate and transparent information relative to the current economic and business environment 
as part of the process  the company reviews the selection  application and communication of critical accounting policies and financial disclosures 
the preparation of our financial statements in conformity with accounting principles generally accepted in the united states requires that our management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period 
we review our estimates and the methods by which they are determined on an ongoing basis 
however  actual results could differ from our estimates 
results of operations comparison of the years ended december  and licensing revenue licensing revenue increased to million in as a result of the up front non refundable licensing payment received from yakult honsha for the rights to commercial and market thermodox in japan 
research and development expenses research and development expenses increased by million  from million in to million in the increase is attributable to clinical trial costs for the primary liver cancer clinical trial and drug manufacturing costs to supply product for the clinical trial 
general and administrative expenses general and administrative expenses decreased by million  from million in to million in the decreases are attributable to a million larger write off to the indemnity reserve and a decrease in salaries due to severance payments made in 
table of contents interest income interest income decreased by 
million from 
million in to 
million in the decrease is attributable to lower interest rates and having less cash available to invest 
interest expense interest expense decreased by 
million from 
million in to 
million in the decrease is attributable to having less debt outstanding in as compared to financial condition  liquidity and capital resources since inception  excluding the million payment from boston scientific received in  we have incurred negative cash flows from operations 
we have financed our operations primarily through the sales of equity and through the divestiture of the medical device business 
our expenses have significantly and regularly exceeded our revenues  and we have an accumulated deficit of million at december  at december   we had total current assets of million including cash and short term investments of million and current liabilities of million  resulting in a working capital surplus of million 
at december   we had total current assets of million including cash and short term investments of million and current liabilities of million  resulting in a working capital surplus of million 
net cash provided by operating activities for the year ended december  was million 
exclusive of the million payment received from boston scientific the net cash used in operations was million 
the million net cash requirement was funded from cash on hand at the beginning of the year and the million account payment collected from boston scientific 
net cash used in financing activities was 
million for the year ended december  which represents the payments made on notes payable 
at december   the company had cash  cash equivalents and short term investments of million and million due from boston scientific in june the million of cash resources is expected to be adequate to fund operations at least through the middle of the company will need substantial additional capital to complete its clinical trials  obtain marketing approvals and to commercialize the products 
off balance sheet arrangements none 
item a 
quantitative and qualitative disclosures about market risk not required 

